Clinical Trial

ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Study withdrawn due to business priority changes
Summary
The ENLIGHT-AML study is a Phase 1, open-label, dose-escalation and expansion study of GB3226 in the treatment of relapsed or refractory acute myeloid leukaemia
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-17.
Status change: Not Yet Recruiting → Withdrawn 2026-07-01
Trial Details
NCT Number NCT07084584
Lead Sponsor Galecto Biotech AB
Conditions Relapsed/Refractory Acute Myeloid Leukemia (AML)
Start Date 2026-06-10
Primary Completion 2029-06-10 (estimated)
Study Completion 2029-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-06